Outcomes with nivolumab in relapsed/refractory follicular lymphoma based on gene expression signature. Progression-free survival (PFS) assessed by independent review committee by level of tumor-associated macrophage genes, TLR5, C3AR1, and FCGR1A. See Figure 4A in the article by Armand et al that begins on page 637.